In light of the rapidly changing coronavirus (COVID-19) situation, Troutman Sanders and Pepper Hamilton have postponed the effective date of their previously announced merger until July 1, 2020. The new firm – Troutman Pepper – will feature 1,100+ attorneys across 23 U.S. offices. Read more.
Pepper Hamilton represented Xenon Pharmaceuticals in its agreement with Neurocrine Biosciences to develop first-in-class treatments for epilepsy.
Under the terms of the license and collaboration agreement, Neurocrine Biosciences will gain rights to XEN901, a clinical-stage selective Nav1.6 sodium channel inhibitor, being developed for the treatment of epilepsy. Xenon will receive $50 million upfront and up to $1.7 billion in potential development, regulatory and commercial milestone payments across all licensed products, as well as the option to co-fund XEN901.
Xenon is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Its novel product pipeline of neurology-focused therapies addresses areas of high unmet medical need, with a focus on epilepsy. The company is located in Burnaby, British Columbia, Canada.
Read more about the agreement at https://finance.yahoo.com/news/neurocrine-biosciences-xenon-pharmaceuticals-announce-123010792.html.